Clinical Trials
66 trialsAtezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
National Cancer Institute (NCI)
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Institutes of Health Clinical Center (CC)
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
National Institutes of Health Clinical Center (CC)
M7824 in Subjects With HPV Associated Malignancies
National Institutes of Health Clinical Center (CC)
Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
National Cancer Institute (NCI)
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
National Cancer Institute (NCI)
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors
National Institute of Allergy and Infectious Diseases (NIAID)
Human Papillomavirus Epidemiology in Nigeria
National Institutes of Health Clinical Center (CC)
Improving Cervical Cancer Screening Among HIV-Infected Women in India
National Institutes of Health Clinical Center (CC)
Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer
National Cancer Institute (NCI)
Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer
National Institutes of Health Clinical Center (CC)
Cervix Image Sharing Protocol (CISP)
National Institutes of Health Clinical Center (CC)
Cervical Cancer Early Endpoints and Determinants
National Institutes of Health Clinical Center (CC)
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
National Cancer Institute (NCI)
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
National Cancer Institute (NCI)
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
National Cancer Institute (NCI)
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
National Cancer Institute (NCI)
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
National Cancer Institute (NCI)
Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
National Cancer Institute (NCI)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
National Cancer Institute (NCI)
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
Low-Cost Molecular Cervical Cancer Screening Study
National Institutes of Health Clinical Center (CC)
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
National Cancer Institute (NCI)
Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer
National Cancer Institute (NCI)
Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer
National Cancer Institute (NCI)
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
National Cancer Institute (NCI)
Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
National Cancer Institute (NCI)
Immunotoxin Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
National Cancer Institute (NCI)
Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix
National Cancer Institute (NCI)
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis
National Cancer Institute (NCI)
Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Diindolylmethane in Treating Patients With Abnormal Cervical Cells
National Cancer Institute (NCI)
Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix
National Cancer Institute (NCI)
Docetaxel in Treating Patients With Advanced Cancer of the Cervix
National Cancer Institute (NCI)
Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
National Cancer Institute (NCI)
SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer
National Cancer Institute (NCI)
EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix
National Cancer Institute (NCI)
Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
National Cancer Institute (NCI)
Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
National Cancer Institute (NCI)
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)